Current technological advances will allow for tailored therapeutic approaches based on a full characterization of AML tumors. Genomic squencing, transcriptional profiling, flow cytometry and metabolomic assays (e.g. evaluation for IDH1/IDH2 mutations, stem cell immunophenotype, mitochondrial mass, mitochondrial priming) will allow for a classification of patients and better identification of actionable therapeutic targets.